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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not Botox is a 
safe and effective treatment to reduce symptoms of depression? Study Design: The review is 
based on three Randomized Control Trials that were double-blind and placebo controlled clinical 
trials. Data Source: All articles were researched and found using PubMed and Medline. The 
articles were selected based on the relevance to my clinical question and if the articles included 
patient oriented outcomes (POEMS). 
 
Outcomes Measured: The outcomes were measured by the improvement of depressive symptoms 
(sleep disturbances, suicide ideations, change in 
appetite/weight/concentration/energy/guilt/interests) and improvement in scores from the 
Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (17 
and 21), Beck Depression Inventory (BDI) and Patient Health Care Questionnaire-9. 
 
Results: In the study by Finzi et al. (2013), they found statistical evidence (p <0.001) that Botox 
improved symptoms of Major Depressive Symptoms. The evidence revealed that 52% of patients 
at 6 weeks showed signs of improvement compared to the placebo group whom showed a 15% 
improvement of symptoms. A study by Magid et al. (2014) also found statistical evidence 
(p<0.001) that treatment with Botox did improve symptoms of Major Depressive Disorder 
(MDD). The study showed that 55% of the patients who received Botox responded to treatment 
and had decreased symptoms with 0% of the placebo group showing any reduction in symptoms. 
A study by Wollmer et al. (2012) also supported the previous evidence with statistical findings 
(p=0.002) that MDD symptoms improved with the use of Botox. Patients had reduced symptoms 
on average of 47% with the use of Botox compared to the placebo group whom had a decrease in 
9.2% of their symptoms. 
 
Conclusion: The results from all three Randomized Control Trials proved that Botox is a safe 
and effective treatment to reduce symptoms of depression. 
 
Key Words: Botulinum Toxins, Depression 
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INTRODUCTION 
Major Depressive Disorder (MDD) is an illness that affects 16% of the US population, 
more than 350 million people worldwide, and is a leading cause of disability internationally.2 In 
the most recent surveys, MDD has the highest lifetime prevalence of any psychiatric disorder 
and patients are at an increased risk for additional comorbid disorders such as alcohol abuse, 
panic disorder, obsessive compulsive disorder and social anxiety.8  
Although there was no exact estimate available for annual health care visits, we know 
that depression affects more than 15 million American adults, or about 6.7 percent of the U.S. 
population age 18 and older in a given year.7 The economic burden of depression was estimated 
at $83.1 billion in 2000 in the United States.5 For employed and treated patients, incremental 
direct costs of health care services were $5,707 per MDD patient in 2005, increasing by 5% in 
2010 to $5,988.5   
The exact etiology of MDD is not clearly defined; however, it is thought to be due to 
either long term effects of chronic stress on the brain from increased cortisol and CRH or from a 
decrease in monoamines (dopamine, serotonin, norepinephrine) causing the brain to up-regulate 
monoamine receptors leading to depression.6 The diagnosis of MDD is obtained through a good 
clinical history.8 The diagnosis is based on the patient having at least 5 symptoms (one must be 
depressed mood or anhedonia) for 2 weeks.6 The symptoms include: sleep disturbance, feeling of 
guilt, decreased energy, decreased concentration, appetite change, psychomotor agitation, and 
suicidal ideations.6  
The most effective intervention for achieving remission and preventing relapse is 
medication, but combined treatment, incorporating psychotherapy to help the patient cope with 
decreased self-esteem and demoralization, improves outcomes.6 The classes of antidepressant 
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medications are serotonin selective reuptake inhibitor (SSRI), serotonin norepinephrine reuptake 
inhibitor (SNRI), norepinephrine dopamine reuptake inhibitor (NDRI), tricyclic antidepressant 
(TCA), and monoamine oxidase inhibitor (MAOI). The available antidepressants do not differ in 
overall efficacy, speed of response, or long-term effectiveness, however, they do differ in their 
pharmacology, drug-drug interactions, short- and long-term side effects, likelihood of 
discontinuation symptoms and ease of dose adjustment.8 A rational approach to selecting which 
antidepressant to use involves matching the patient’s preference and medical history with the 
metabolic and side effect profile of the drug.6  
Troubling side effects from the use of antidepressants, such as decreased libido, 
anorgasmia, insomnia and nausea, are a major reason why patients discontinue treatment and 
subsequently relapse.1 A relevant proportion of patients do not sufficiently improve with 
medication management and psychotherapy and are often left with fewer therapeutic options.2 
The use of Ontabotulinumtoxin A (Botox) may be used as an adjunct to anti-depressant 
medications or psychotherapy for the treatment of depressive symptoms. 
The theories behind why Botox may be effective for treatment of MDD and its 
mechanism of action is through the facial feedback hypothesis.1 The hypothesis suggests that 
facial expression influences emotional perception; producing an expression that is characteristic 
of a particular emotion can lead to experiencing an emotion (eg, smiling can lead to happiness, 
scowling can lead to anger).2 One study showed that mimicking facial expressions of anger or 
fear, even with no emotional valence attached to the expression, can lead to significant changes 
in heart rate and temperature.2 Injecting Botox into the muscles responsible for expression of 
anguish or sadness may potentially decrease the patients experience of feelings.1,2 Botox 
reversibly blocks acetylcholine release from neuronal axons into the synapse, inhibiting 
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neuromuscular transmission.2 If the facial feedback hypothesis is correct, by injecting Botox into 
the corrugator and procerus muscles, it will reversibly inhibit frown facial expressions and have 
the capability of propagating or enhancing sad and depressed feelings.1 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not Botox is a safe 
and effective treatment to reduce symptoms of depression. 
METHOD 
The studies that are evaluated in this systemic review are three randomized control trials that 
were double-blind with placebo controlled trials. The articles were researched through PubMed 
and Medline and all three articles were published in English between 2012 and 2014. The 
keywords that were searched in PubMed and Medline were “Botulinum Toxins” and 
“Depression”. Articles were selected based on the relevance to my clinical question and if the 
articles included patient oriented outcomes (POEMS). 
The criteria used for the selection of each study was based on the population study, 
intervention, comparisons group and the outcomes of each study. The population being studied 
in the three studies included men and women between the age of 18 and 65 with an ongoing 
diagnosis of MDD. Wollmer et al.3 varied in that it only used patients between the ages of 25 and 
65. 
The intervention being used in all three studies was Ontabotulinumtoxin A, 29U for women 
and 39U for men. For women, 7U was injected into the procerus muscle and 6U was injected 
bilaterally to the medial part of the corrugator muscles and 5U bilaterally to the middle part of 
the corrugator muscle. For men, 9U was injected into the procerus muscle and 8U was injected 
bilaterally to the medial part of the corrugator muscles and 7U bilaterally to the middle part of 
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the corrugator muscle. The Botox was compared to the use of a placebo, 0.9%NaCl solution, 
which used the same number of units injected into the same locations as the Botox. 
The inclusion criteria for all three studies included randomized control trials that were 
double-blind, all included relevant POEMS, all patients were over 18 years old, patients had an 
ongoing diagnosis of MDD, and all studies evaluated the efficacy of Botox on MDD. The 
exclusion criteria included patients that were under the age of 18, had an active substance abuse 
problem, had an unstable medical condition or had previous Botox treatments. The statistical 
analyses were reported by p-values, NNT, RBI and ABI. Table 1 represents the demographics 
and characteristics of each study. 
OUTCOMES MEASURED 
 All three studies were measuring outcomes by improvement of major depressive 
symptoms and improvement of scores on self-rating questionnaires. Finzi et al. measured their 
outcomes based on the Montgomery and Asberg Depression Rating Scale (MADRS) and Beck 
Depression Inventory (BDI) which is filled out by the patient and the Clinical Global Impression 
(CGI) which is filled out by a clinician.1 Magid et al. measured their outcomes primarily with 
patient questionnaires such as the Patient Health Care Questionnaire-9, BDI and 21-item 
Hamilton Depression Rating Scale.2 Wollmer et al. measured outcomes using the 17-item 
Hamilton Depression Rating Scale, BDI, CGI scale and four-point clinical severity score for 
Glabellar Frown Lines.3 
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Table 1: Demographics and characteristics of included studies 
Study Type # 
Pts 
Age Inclusion 
Criteria 
Exclusion Criteria W/
D 
Intervention 
Finzi 
(2013)1 
Double 
Blind 
RCT 
85 18-
65 
Outpatient men 
and women 
aged 18-65 with 
a DSM-IV 
diagnosis of 
MDD. Patients 
must have 
MADRS score 
>26 and a 
Clinical Global 
impression 
Severity >4. 
Patients with 
another Axis I 
disorder, substance 
abuse history, illicit 
drug use, attempted 
suicide in past 6 
months, unstable 
medical condition, 
treated with OBA 
in past 12 months, 
change in 
medication regimen  
0 Single 
injection of 
Ontabotulin
umtoxinA 
vs. placebo 
group 
receiving 
0.9% NaCl 
(29U for 
women and 
39U for 
men) 
Magid 
(2014)2 
Double 
Blind 
RCT 
30 18-
65 
Men and 
women ages 18-
65 with a 
history of MDD 
for at least 6 
months as 
defined by 
DSM-IV 
criteria. Patients 
must have 
scored a 14 or 
greater on the 
21-Item 
Hamilton 
Depression 
Rating Scale 
Active substance 
abuse, bipolar 
disorder, 
pregnancy, unstable 
medical condition, 
previous Botox 
treatment, treatment 
with > 3 
psychotropic 
medications, 
another axis H 
comorbidity  
0 Single 
injection of 
Ontabotulin
umtoxinA 
vs. placebo 
group 
receiving 
0.9% NaCl 
(29U for 
women and 
39U for 
men) 
Wollmer 
(2012)3 
Double 
Blind 
RCT 
30 25-
65 
Men and 
women age 25-
65 with a 
diagnoses of 
on-going MDD 
and taking 1-2 
antidepressants 
for at least 4 
weeks and have 
a moderate to 
severe vertical 
glabellar line. 
Psychotic 
symptoms, suicide 
tendency, untreated 
depressed, another 
DSM-IV axis I 
diagnosis, 
personality 
disorder, severe 
PMS/PMDD, 
regular migraines, 
contraindications of 
Botox, previous 
treatment with 
Botox 
0 Single 
injection of 
Ontabotulin
umtoxinA 
vs. placebo 
group 
receiving 
0.9% NaCl 
(29U for 
women and 
39U for 
men) 
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RESULTS 
 All three randomized control double-blind trials in this systemic review used the methods 
previously described to determine the efficacy of using Botox to treat MDD in comparison to a 
placebo of 0.9% NaCl over a six-week period.  
In the study by Finzi et al.1, 74 subjects were randomly selected in the double-blind 
study, 33 in the Onabotulinumtoxin A group (OBA) and 41 in the placebo group with very minor 
demographic differences between the OBA group and placebo group. The participants were 
required to complete initial MADRS questionnaires. The participants were followed up with the 
same questionnaires at week 3 and week 6 to determine the efficacy of Botox. At week 6, 52% of 
the participants in the OBA group had improved depressive symptoms compared to the 15% in 
the placebo group. The two groups were compared statistically by calculating a p-value of 
<0.001. Since the p-value is < 0.5 the treatment is statistically significant. Table 3 outlines the 
mean MADRS scores between the OBA group and the placebo group. The table outlines a 
significant decrease in scores in the OBA group at week 0 (31.6) and week 6 (16.9) in 
comparison to a slighter decrease in the placebo group at week 0 (31.2) and week 6 (24.6).  
Table 2: Mean MADRS scores over time 
 Week 0 Week 3 Week 6 
OBA 31.6 18.9 16.9 
Placebo 31.2 24.9 24.6 
 
In the Magid et al.2 study, there were 30 participants enrolled with 11 patients receiving 
Onabotulinumtoxin A (BTA group) and 19 in the placebo group. Participants were monitored at 
week 0, week 6, week 12 and week 24. This study included a crossover at week 12, however, 
analysis was given for the initial 6 weeks then again after the crossover at week 24. In an attempt 
to compare equivalent data, only the data from week 6 of each trial was used in this systemic 
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review. At week 6, the response rate for BTA group was 55% and 0% for the placebo group. The 
study found statistical evidence (p <0.001) that treatment with Botox did improve symptoms of 
MDD. 
 In the Wollmer et al. study, there were 30 participants divided equally between the Botox 
group and the placebo group. After 6 weeks of treatment, the Botox recipients’ symptoms were 
reduced by 47.1% and the placebo by 9.2%. The study also supported previous evidence with 
statistical findings (p=0.002) that MDD symptoms improve with the use of Botox. 
Dichotomous data was used in all three studies. The Relative Benefit Increase (RBI), 
Absolute Benefit Increase (ABI) and Numbers Needed To Treat (NNT) were calculated for all 
three studies to determine the efficacy of Botox after six weeks of treatment. The data can be 
found in Table 3. The NNT for all three studies shows that for every 2-3 patients treated with 
Botox, one more will have benefit of treatment from Botox and relief of symptoms at six weeks 
compared to the control group.  
Table 3: Efficacy of Onabotulinumtoxin A in MDD symptoms at six weeks 
 CER EER RBI ABI NNT 
Finzi et al. 15% 52% 71.15% 37% 2.7 
Magid et al. 55% 0% 100% 55% 1.8 
Wollmer et. al 9.2% 47.1% 80.9% 37.9% 2.6 
 
Safety and tolerability was evaluated in the Finzi et al. and Wollmer et al. study. Table 4 
shows the analysis of safety and tolerability of Botox and the placebo (NaCl 0.9%) in both 
studies by calculating the Numbers Needed To Harm (NNH). In the Finzi et. al study the NNH 
was -7.5 meaning that for every 7.5 patients exposed to the treatment, 1 fewer will develop an 
adverse reaction compared to the control group. Only 3 adverse reactions occurred during the 
study and 2 of the 3 occurred in the placebo group. In the placebo group one patient experienced 
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vivid dreams and headaches while the second participant experienced headaches. In the 
experimental group only one patient complained of headaches. In comparison, the Wollmer et al. 
study had a NNH of -50 meaning that for every 50 patients treated with Botox, 1 fewer will 
develop an adverse reaction compared to the control group. The main adverse effects in this 
study included short episodes of headaches during the first few weeks of trial and occurred in 
both the experimental and placebo group. There were no adverse reactions noted or evaluated in 
the Magid et al. study. 
Table 4: Safety and Tolerability of Botox vs Nacl 0.9% injection 
 CER EER RRI ARI NNH 
Finzi et al. 40% 26.7% -33% -13.3% - 7.5 
Wollmer et. al 5% 3% -0.4 -2 - 50 
 
DISCUSSION 
 Botox is currently FDA approved for many conditions in adults such as chronic 
migraines, upper limb spasticity, cervical dystonia, axillary hyperhidrosis, blepharospasm, and 
strabismus.9 The contraindications to use of Botox are any hypersensitivity reactions or infection 
at the site of injection. There are many adverse reactions with the use of Botox for other 
conditions that range from non-life threatening such as headaches to life threatening such as 
death. For example, Botox used for cervical dystonia most commonly causes an adverse reaction 
of dysphagia but can also weaken accessory muscles that are necessary for adequate ventilation.9 
If these muscles were to become weakened and the use of Botox was continued patients could 
develop swallowing or breathing difficulties ultimately leading to death.9 The three studies 
evaluated in this systemic review resulted in only non-life threatening adverse reactions, most 
notably headaches.  
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 There were many limitations noted about all three studies. All three studies included a 
small sample size of either 30 or 85 participants which may not provide enough sufficient 
evidence to represent the true effectiveness of Botox in the MDD population. All three studies 
were also female dominant with 93% of the Finzi et al. participants, 90% of the Magid et al. 
participants and 78% of the Wollmer participants being female. Having a majority of the 
participants being female does not provide any statistical analysis of effectiveness based on 
gender. In addition, all three studies used Botox as an adjunct therapy to antidepressants or 
psychotherapy and not as monotherapy. 
CONCLUSION 
 Based on the systemic review, Botox is a safe and effective treatment to reduce the 
symptoms of depression; however, it is not proven if Botox is an effective treatment as 
monotherapy to reduce the symptoms of depression. All three studies showed significant 
improvement of MDD symptoms with the use of Botox in the experimental group versus the 
controlled group in a six-week period. 
 Future studies need to evaluate the use of Botox as monotherapy. This would allow the 
treatment to be cost effective and patients would be more compliant as they would not have to 
remember to take a medication every day. Future studies should also consider evaluating the 
subjects for a longer duration to be able to provide adequate information on the length of time 
each injection could potentially last. Additionally, more research should be done to evaluate the 
potential long-term side effects from the use of Botox as continual therapy. 
In conclusion, the systemic review proved that Botox is a safe and effective treatment to 
reduce the symptoms of depression; however, continued research should be done to evaluate the 
use of Botox as monotherapy and as long-term treatment.
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